Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Song

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
The Journal of Dermatological Treatment|August 12, 2017
Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trialApril Armstrong, Luis Puig, Richard Langley, et al.
The Journal of Dermatological Treatment|July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1Christopher E M Griffiths, Kim A Papp, Michael Song, et al.
Current Issues in Molecular Biology|September 25, 2021
HPRep: Quantifying Reproducibility in HiChIP and PLAC-Seq DatasetsJonathan D Rosen, Yuchen Yang, Armen Abnousi, et al.
Elife|May 25, 2019
Live-cell imaging reveals enhancer-dependent <i>Sox2</i> transcription in the absence of enhancer proximityJeffrey M Alexander, Juan Guan, Bingkun Li, et al.
International Journal of Geriatric Psychiatry|June 2, 2012
Cognitive differences among depressed and non-depressed MCI participants: a project FRONTIER studyLeigh A Johnson, Cortney Mauer, Danielle Jahn, et al.
European Journal of Public Health|August 8, 2018
Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: At Home/Chez Soi Study, Vancouver, BCNooshin Nikoo, Sanam Javidanbardan, Moniruzzaman Akm, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
The Journal of Dermatological Treatment|August 12, 2017
Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trialApril Armstrong, Luis Puig, Richard Langley, et al.
The Journal of Dermatological Treatment|July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1Christopher E M Griffiths, Kim A Papp, Michael Song, et al.
Current Issues in Molecular Biology|September 25, 2021
HPRep: Quantifying Reproducibility in HiChIP and PLAC-Seq DatasetsJonathan D Rosen, Yuchen Yang, Armen Abnousi, et al.
Elife|May 25, 2019
Live-cell imaging reveals enhancer-dependent <i>Sox2</i> transcription in the absence of enhancer proximityJeffrey M Alexander, Juan Guan, Bingkun Li, et al.
International Journal of Geriatric Psychiatry|June 2, 2012
Cognitive differences among depressed and non-depressed MCI participants: a project FRONTIER studyLeigh A Johnson, Cortney Mauer, Danielle Jahn, et al.
European Journal of Public Health|August 8, 2018
Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: At Home/Chez Soi Study, Vancouver, BCNooshin Nikoo, Sanam Javidanbardan, Moniruzzaman Akm, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Pageof 7